Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Hanauer

Showing results (31-40 of 62) with videos related to

Pageof 7
Sort By:
Frontline Gastroenterology|April 11, 2022
Pancreatitis associated with azathioprine and 6-mercaptopurine use in Crohn's disease: a systematic reviewMorris Gordon, Ciaran Grafton-Clarke, Anthony Akobeng, et al.
Inflammatory Bowel Diseases|April 17, 2019
Letter to the Editor: Patients With Inflammatory Bowel Disease Demonstrate an Inherent Lack of PsychopathologyTiffany H Taft, Sarah Quinton, Kathryn Tomasino, et al.
Plos One|March 6, 2012
Standard colonic lavage alters the natural state of mucosal-associated microbiota in the human colonLaura Harrell, Yunwei Wang, Dionysios Antonopoulos, et al.
Journal of Crohn'S & Colitis|April 10, 2014
Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseasesWilliam J Sandborn, Stephen Hanauer, Gert Van Assche, et al.
The American Journal of Gastroenterology|July 18, 2023
P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North StudyDavid Hudesman, Millie Long, Douglas Wolf, et al.
Journal of Crohn'S & Colitis|February 7, 2019
Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical TrialsStephen Hanauer, William J Sandborn, Jean-Frederic Colombel, et al.
Journal of Clinical Apheresis|December 21, 2002
First two patients with ulcerative colitis who developed classical thrombotic thrombocytopenic purpura successfully treated with medical therapy and plasma exchangeBeverly W Baron, Hye-Ran Jeon, Catherine Glunz, et al.
The American Journal of Gastroenterology|September 28, 2004
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's diseaseWilliam J Sandborn, Stephen Hanauer, Edward V Loftus, et al.
Crohn'S & Colitis 360|February 13, 2023
Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients With Chronic Abdominal Pain Associated With Crohn's DiseaseBruce R Yacyshyn, Stephen Hanauer, Preston Klassen, et al.
Gut|July 5, 2012
A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's diseaseBruce E Sands, Seymour Katz, Douglas C Wolf, et al.
Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
Frontline Gastroenterology|April 11, 2022
Pancreatitis associated with azathioprine and 6-mercaptopurine use in Crohn's disease: a systematic reviewMorris Gordon, Ciaran Grafton-Clarke, Anthony Akobeng, et al.
Inflammatory Bowel Diseases|April 17, 2019
Letter to the Editor: Patients With Inflammatory Bowel Disease Demonstrate an Inherent Lack of PsychopathologyTiffany H Taft, Sarah Quinton, Kathryn Tomasino, et al.
Plos One|March 6, 2012
Standard colonic lavage alters the natural state of mucosal-associated microbiota in the human colonLaura Harrell, Yunwei Wang, Dionysios Antonopoulos, et al.
Journal of Crohn'S & Colitis|April 10, 2014
Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseasesWilliam J Sandborn, Stephen Hanauer, Gert Van Assche, et al.
The American Journal of Gastroenterology|July 18, 2023
P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North StudyDavid Hudesman, Millie Long, Douglas Wolf, et al.
Journal of Crohn'S & Colitis|February 7, 2019
Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical TrialsStephen Hanauer, William J Sandborn, Jean-Frederic Colombel, et al.
Journal of Clinical Apheresis|December 21, 2002
First two patients with ulcerative colitis who developed classical thrombotic thrombocytopenic purpura successfully treated with medical therapy and plasma exchangeBeverly W Baron, Hye-Ran Jeon, Catherine Glunz, et al.
The American Journal of Gastroenterology|September 28, 2004
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's diseaseWilliam J Sandborn, Stephen Hanauer, Edward V Loftus, et al.
Crohn'S & Colitis 360|February 13, 2023
Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients With Chronic Abdominal Pain Associated With Crohn's DiseaseBruce R Yacyshyn, Stephen Hanauer, Preston Klassen, et al.
Gut|July 5, 2012
A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's diseaseBruce E Sands, Seymour Katz, Douglas C Wolf, et al.
Pageof 7